Table 2 Distribution of clinicopathological parameters in 1,000 high-risk breast cancer patients
|  |  | Radiotherapy | No radiotherapy | χ2 |
|---|---|---|---|---|
All | Â | 489 (49%) | 511 (51%) | Â |
Protocol | Pre (DBCG82b) | 267 (54%) | 296 (58%) | 0.3 |
| Â | Post (DBCG82c) | 222 (46%) | 215 (42%) | Â |
Tumour size (mm) | <21 | 171 (35%) | 190 (37%) | 0.1 |
| Â | 21 to 50 | 259 (53%) | 242 (47%) | Â |
| Â | >50 | 59 (12%) | 79 (15%) | Â |
Positive nodes | None | 29 (6%) | 31 (6%) | 0.8 |
| Â | 1 to 3 | 222 (46%) | 220 (43%) | Â |
| Â | >3 | 238 (49%) | 260 (51%) | Â |
Histopathology | Ductal | 428 (88%) | 427 (84%) | 0.1 |
| Â | Nonductal | 61 (12%) | 84 (16%) | Â |
Malignancy grade (ductal only) | Grade 1 | 98 (23%) | 97 (23%) | 0.7 |
| Â | Grade 2 | 213 (50%) | 223 (52%) | Â |
| Â | Grade 3 | 117 (27%) | 107 (25%) | Â |
ER | Positive | 327 (67%) | 344 (67%) | 0.4 |
| Â | Negative | 160 (33%) | 167 (33%) | Â |
| Â | Unknown | 2 (0%) | 0 (0%) | Â |
PgR | Positive | 283 (58%) | 313 (61%) | 0.3 |
| Â | Negative | 205 (42%) | 198 (39%) | Â |
| Â | Unknown | 1 (0%) | 0 (0%) | Â |
HER2 | Negative | 376 (77%) | 404 (79%) | 0.6 |
| Â | Positive | 110 (22%) | 106 (21%) | Â |
| Â | Unknown | 3 (1%) | 1 (0%) | Â |
CA IX | Negative | 386 (79%) | 408 (80%) | 0.3 |
| Â | Positive | 80 (16%) | 71 (14%) | Â |
| Â | Unknown | 23 (5%) | 32 (6%) | Â |